<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01556542</url>
  </required_header>
  <id_info>
    <org_study_id>Arezzo004</org_study_id>
    <nct_id>NCT01556542</nct_id>
  </id_info>
  <brief_title>Drug Eluting Balloon in peripherAl inTErvention SFA</brief_title>
  <acronym>DEBATE SFA</acronym>
  <official_title>Drug Eluting Balloon in peripherAl inTErvention: the DEBATE SFA Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leonardo Bolognese, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ospedale San Donato</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of drug-eluting balloon angioplasty
      followed by nitinol stent implantation versus nitinol stent implantation in superficial
      femoral artery and popliteal artery stenosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>angiographic binary restenosis</measure>
    <time_frame>12 months</time_frame>
    <description>incidence of binary restenosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>major amputation</measure>
    <time_frame>24 months</time_frame>
    <description>incidence of major amputation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target lesion revascularization</measure>
    <time_frame>24 months</time_frame>
    <description>incidence of target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vessel reocclusion</measure>
    <time_frame>24 months</time_frame>
    <description>incidence of vessel reocclusion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>standard PTA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nitinol stent implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DEB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation</intervention_name>
    <description>paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation</description>
    <arm_group_label>DEB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>nitinol stent implantation</intervention_name>
    <description>nitinol stent implantation</description>
    <arm_group_label>standard PTA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age&gt;18 years

          -  intermittent claudication(Fontane III or IV)

          -  angiographic stenosis&gt;50% or occlusion of superficial femoral-popliteal artery&gt;40mm

          -  at least one below-knee vessel to the ankle

        Exclusion Criteria:

          -  allergy to Paclitaxel

          -  contraindication for combined antiplatelet treatment

          -  life expectancy &lt;1 year

          -  hypersensitivity or contraindication to one of the study drugs

          -  lack of consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Liistro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Department, San Donato Hospital, Arezzo, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiovascular Department, Ospedale S.Donato</name>
      <address>
        <city>Arezzo</city>
        <state>AR</state>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2012</study_first_submitted>
  <study_first_submitted_qc>March 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2012</study_first_posted>
  <last_update_submitted>January 26, 2013</last_update_submitted>
  <last_update_submitted_qc>January 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale San Donato</investigator_affiliation>
    <investigator_full_name>Leonardo Bolognese, MD</investigator_full_name>
    <investigator_title>Director of Cardiovascular Department</investigator_title>
  </responsible_party>
  <keyword>peripheral arterial disease</keyword>
  <keyword>drug-eluting balloon</keyword>
  <keyword>restenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

